Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

ogress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

According to the National Multiple Sclerosis Society, approximately 400,000 Americans acknowledge having MS, and every week about 200 people are diagnosed. Worldwide, multiple sclerosis may affect 2.5 million individuals.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indication in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adv
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Feb. 10, 2011 ,We are in a State of ... message that concerned Florida residents are desperate for people to hear. ... day due to prescription drug abuse and statistics show it is ... (FAADA) is calling for an immediate Congressional hearing to help put ...
... Feb. 10, 2011 For the biopharmaceutical industry, ... - and difficulty - of interacting with patients ... have created both opportunities and challenges for approaching ... To help marketing teams in the ...
Cached Medicine Technology:Parents, Physicians Unite and Declare: State of Emergency 2Parents, Physicians Unite and Declare: State of Emergency 3Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... an efficient, effective way to analyze wounds from bullets and ... the March issue of Radiology . "The ... care and aid in both military and civilian forensic investigations," ... from the Uniformed Services University in Bethesda, Md. U.S. ...
... Extremely obese people had a significantly greater chance of dying ... that became a pandemic last winter, a new study reports. ... with H1N1 flu during the first four months of 2009 ... three-fold increased risk for death. Extreme obesity is defined ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, Jan. ... the risk of autism in the second child, new research ... within a year of their older sibling. Babies conceived within ... their older sibling were also at a heightened risk of ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Widespread ... a 5 percent drop in available nursing home beds across ... research reveals. "The country,s minority population is aging at ... lead author Zhanlian Feng, an assistant professor of community health ...
... is well known that pain is a highly subjective experience. ... depending on distractions and mood. A paper in the ... cautionary note on measuring perceived pain in research. There ... symptoms other than pain, but because of the subjectivity in ...
... report a gene therapy strategy that improves the condition ... Beta Thalassemia. The gene correction involves using unfertilized ... embryonic stem cell lines. Some of these stem cell ... thus be used for transplantation-based treatments of the same ...
Cached Medicine News:Health News:CT helps identify bullet trajectories 2Health News:Closely Spaced Pregnancies Might Up Autism Risk: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 3Health News:Does it hurt? 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 3
Female High Waist Briefs...
Provides upper and lower arm and flank support. Extends to the wrist and over the full upper back. Has a thin strap above the breast and a 3 waistband for a secure, comfortable fit. Made of soft span...
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Breast Augmentation Wrap...
Medicine Products: